Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

NIH 7INDUSTRY 5OTHER 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Endometrial Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 262Specimen Handling 253pembrolizumab 230Cyclophosphamide 216Radiotherapy 204Nivolumab 168Cisplatin 161Carboplatin 145Biopsy 144Radiosurgery 128fludarabine 123Blood Specimen Collection 116Gemcitabine 111Paclitaxel 107Surveys and Questionnaires 106Standard of Care 102venetoclax 94Dexamethasone 93Bevacizumab 92Radiation 87Rituximab 81Capecitabine 80Cytarabine 79Oxaliplatin 77Drug Therapy 75Doxorubicin 75Ipilimumab 73durvalumab 70fludarabine phosphate 69atezolizumab 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × ipatasertib × 90 days × Clear all
NCT05498896 2026-05-08

BARBICAN

Queen Mary University of London

Phase 2 Active not recruiting
146 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04920708 2026-04-14

FAIM

Royal Marsden NHS Foundation Trust

Phase 2 Active not recruiting
57 enrolled
Breast

Breast Neoplasms

NCT04486352 2026-04-01

EndoMAP

Alliance Foundation Trials, LLC.

Phase 1/2 Recruiting
148 enrolled
Gynecologic

Endometrial Neoplasms

NCT04253561 2026-03-16

IPATHER

SOLTI Breast Cancer Research Group

Phase 1 Completed
17 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡